Table 1.
Association of Anti‐Rb antibodies with SLE manifestations
| Manifestations | Anti‐Rb Positive (N = 15), n (%) | Anti‐Rb Negative (N = 207), n (%) | P a | OR (95% CI) |
|---|---|---|---|---|
| Vasculitis ever | 0 (0.00) | 34 (16.43) | 0.1353 | N/Cb |
| Proteinuria ever | 0 (0.00) | 76 (36.71) | 0.0031 | N/Cb |
| Hematuria ever | 1 (6.67) | 44 (21.26) | 0.3155 | 0.27 (0.01‐1.72) |
| Renal SLE ever (hematuria or proteinuria) | 1 (6.67) | 82 (39.61) | 0.0111 | 0.11 (0.01‐0.69) |
| Stroke ever | 2 (13.33) | 4 (1.93) | 0.0547 | 7.65 (0.95‐45.25) |
| Anemia ever | 1 (6.67) | 126 (60.87) | <0.0001 | 0.05 (0.01‐0.29) |
| Heart murmur ever | 2 (13.33) | 83 (40.10) | 0.0525 | 0.23 (0.04‐1.06) |
| Moon facies ever | 0 (0.00) | 48 (23.19) | 0.0454 | N/Cb |
| Pulse steroid use ever | 1 (6.67) | 71 (34.30) | 0.0414 | 0.14 (0.01‐0.87) |
| Cytotoxic use ever | 3 (20.00) | 108 (52.17) | 0.0293 | 0.23 (0.05‐0.86) |
| Malignancy | 2 (13.33) | 36 (17.65) | 1.0000 | 0.72 (0.11‐3.08) |
| SLE antibodies | ||||
| Anti‐Ro | 4 (26.67) | 66 (32.04)c | 0.7801 | 0.77 (0.22‐2.65) |
| Anti‐La | 1 (6.67) | 32 (15.53)c | 0.7051 | 0.39 (0.02‐2.59) |
| Anti‐RNP | 1 (6.67) | 36 (17.39) | 0.4756 | 0.34 (0.02‐2.23) |
| Anti‐Smith | 1 (6.67) | 35 (16.91) | 0.4752 | 0.35 (0.02‐2.32) |
| Anti‐dsDNA | 6 (40.00) | 127 (61.35) | 0.1705 | 0.42 (0.14‐1.25) |
| RVVT | 2 (13.33) | 71 (34.30) | 0.1524 | 0.30 (0.05‐1.37) |
| Anticardiolipin | 9 (60.00) | 125 (60.39) | 1.0000 | 0.98 (0.33‐2.89) |
| Coombs | 1 (6.67) | 33 (15.94) | 0.4776 | 0.38 (0.02‐2.50) |
| Any of the selected antibodies | 11 (73.33) | 189 (91.30)d | 0.0477 | 0.26 (0.08‐0.98) |
Abbreviation: CI, confidence interval; dsDNA, double‐stranded DNA; N/C, not calculated; OR, odds ratio; Rb, retinoblastoma; RNP, ribonucleoprotein; RVVT, russell viper venom test; SLE, systemic lupus erythematosus.
a
Fisher's exact test.
b
OR was not calculated because of zero cell frequencies.
c
One patient with negative anti‐Rb was dropped because the patient did not have anti‐Ro and anti‐La tests done.
d
Three patients with negative anti‐Rb had missing information on malignancy and were dropped.